Global Adeno-Associated Virus Vector-Based Gene Therapy Market: By Therapeutic Application: Neurological Disorders, Ophthalmic Disorders, Muscular Disorders, Hematological Disorders, Metabolic Disorders; By Target Disease: Rare Diseases, Cancer, Inherited Genetic Disorders; By End User; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Overview 
    3.1    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Historical Value (2017-2023) 
    3.2    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Forecast Value (2024-2032)
4    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Landscape*
    4.1    Global Adeno-Associated Virus Vector-Based Gene Therapy: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Adeno-Associated Virus Vector-Based Gene Therapy: Product Landscape
        4.2.1    Analysis by Therapeutic Application    
        4.2.2    Analysis by Application
5    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentation (2017-2032)
    6.1    Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        6.1.1    Market Overview
        6.1.2    Neurological Disorders
        6.1.3    Ophthalmic Disorders
        6.1.4    Muscular Disorders
        6.1.5    Hematological Disorders
        6.1.6    Metabolic Disorders
    6.2    Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        6.2.1    Market Overview
        6.2.2    Rare Diseases
        6.2.3    Cancer
        6.2.4    Inherited Genetic Disorders
    6.3    Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by End User
        6.3.1    Market Overview
        6.3.2    Hospitals and Clinics
        6.3.3    Research Institutes and Universities
        6.3.4    Biotechnology and Pharmaceutical Companies
    6.4    Global Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Region
        6.4.1    Market Overview
        6.4.2    North America
        6.4.3    Europe 
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
    7.1    North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        7.1.1    Market Overview    
        7.1.2    Neurological Disorders
        7.1.3    Ophthalmic Disorders
        7.1.4    Muscular Disorders
        7.1.5    Hematological Disorders
        7.1.6    Metabolic Disorders
    7.2    North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        7.2.1    Market Overview
        7.2.2    Rare Diseases
        7.2.3    Cancer
        7.2.4    Inherited Genetic Disorders
    7.3    North America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
    8.1    Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        8.1.1    Market Overview    
        8.1.2    Neurological Disorders
        8.1.3    Ophthalmic Disorders
        8.1.4    Muscular Disorders
        8.1.5    Hematological Disorders
        8.1.6    Metabolic Disorders
    8.2    Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        8.2.1    Market Overview
        8.2.2    Rare Diseases
        8.2.3    Cancer
        8.2.4    Inherited Genetic Disorders
    8.3    Europe Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
    9.1    Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        9.1.1    Market Overview    
        9.1.2    Neurological Disorders
        9.1.3    Ophthalmic Disorders
        9.1.4    Muscular Disorders
        9.1.5    Hematological Disorders
        9.1.6    Metabolic Disorders
    9.2    Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        9.2.1    Market Overview
        9.2.2    Rare Diseases
        9.2.3    Cancer
        9.2.4    Inherited Genetic Disorders
    9.3    Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
    10.1     Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        10.1.1    Market Overview    
        10.1.2    Neurological Disorders
        10.1.3    Ophthalmic Disorders
        10.1.4    Muscular Disorders
        10.1.5    Hematological Disorders
        10.1.6    Metabolic Disorders
    10.2     Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        10.2.1    Market Overview
        10.2.2    Rare Diseases
        10.2.3    Cancer
        10.2.4    Inherited Genetic Disorders
    10.3    Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032)
    11.1     Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Therapeutic Application
        11.1.1    Market Overview    
        11.1.2    Neurological Disorders
        11.1.3    Ophthalmic Disorders
        11.1.4    Muscular Disorders
        11.1.5    Hematological Disorders
        11.1.6    Metabolic Disorders
    11.2     Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Target Disease
        11.2.1    Market Overview
        11.2.2    Rare Diseases
        11.2.3    Cancer
        11.2.4    Inherited Genetic Disorders
    11.3    Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory  Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent  Analysis
    13.1     Analysis by Type of Patent
    13.2     Analysis by Publication Year
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Patent Age
    13.5     Analysis by CPC Analysis
    13.6     Analysis by Patent Valuation 
    13.7     Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Application
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1     Analysis by Funding Instances
    15.2     Analysis by Type of Funding
    15.3     Analysis by Funding Amount
    15.4     Analysis by Leading Players
    15.5     Analysis by Leading Investors
    15.6     Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Type of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1    Market Share by Top 5 Companies 
    17.2    Arya Sciences Acquisition Corp.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications 
    17.3    Pfizer Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    BioMarin Pharmaceutical Inc. 
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Bayer AG
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Coave Therapeutics
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    MeiraGTx Limited
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Neurocrine Biosciences, Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Biogen, Inc. 
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications Mergers and Acquisitions
        17.9.6    Certifications
    17.10    Sangamo Therapeutics 
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11     Sarepta Therapeutics, Inc. 
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
18    Global Adeno-Associated Virus Vector-Based Gene Therapy Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)
    20.1     Very Small Companies
    20.2     Small Companies
    20.3     Mid-Sized Companies
    20.4     Large Companies
    20.5     Very Large Companies
21    Payment Methods (Additional Insight)
    21.1     Government Funded
    21.2     Private Insurance
    21.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.